No profile data available.
PDS Biotechnology Corporation (PDSB) is a healthcare company in the additional cancer treatment drugs industry, based in Princeton, United States, with about 21 full-time employees.
It reported revenue of $0 for fiscal year 2024, and net income of -$37.61 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $0. Its market capitalization was $100.01 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
PDS Biotechnology reported $0 in revenue for fiscal year 2024. In Q3 2025 revenue was $0.
$100.01 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Black Diamond Therapeutics, Inc. (BDTX), Corbus Pharmaceuticals Holdings, Inc. (CRBP), Anixa Biosciences, Inc. (ANIX), OnKure Therapeutics, Inc. (OKUR).